A5322: Long-Term Follow-up of Older HIV-infected Adults in the ACTG: Addressing Issues of Aging, HIV Infection and Inflammation – HAILO

Study Location:

Baltimore

Topic:

HIV

Clinicaltrials.gov Link:

N/A

IRB#:

NA_00086904

Coordinator:

Abby Dowling, RN

Enrollment:

Closed

Trial Period:

Ongoing

The A5322 protocol is a long-term observational study, with a planned series of analyses of data to be collected from an established longitudinal study of HIV-infected participants. At the time of enrollment in A5322, these participants were enrolled and followed in the Adult AIDS Clinical Trials Group Longitudinal Linked Randomized Trials (ALLRT) study (A5001) (or had recently completed follow-up in ALLRT [A5001]), which had enrolled participants who received their first immune-based or antiretroviral therapies (ART) or treatment strategies through randomized ACTG clinical trials.  

Participants actively followed in the ALLRT (A5001) at the time of enrollment into A5322 or completed follow-up in ALLRT (A5001) who were ART-naïve at the time of enrollment into their ALLRT (A5001) parent protocol, and who were 40 years of age or older at their time of enrollment into A5322.

410-955-2898

Categories

Location
Topic

Clinical Trials

A5354/EARLIER: Effect of Antiretroviral Treatment Initiated...

This study will include people who have very recently been infected with HIV and will start anti-HIV (antiretroviral) drugs...

Read More

HPTN 078: Enhancing Recruitment, Linkage to Care and...

The purpose of this study is to develop and assess the efficacy of an integrated strategy that includes feasible and scalable...

Read More

A5207, Maintaining Options for Mothers Study (MOMS): A Phase...

A major disadvantage of giving SD NVP is the potential for maternal development of NVP resistance and additional resistance to...

Read More

HPTN 069: A Phase II Randomized, Double-Blind, Study of the...

HPTN 069 is a phase II, four-arm, multisite, randomized, double-blinded trial. To assess the safety and tolerability of four...

Read More

A5290: Randomized, Phase 2b Study of a Double-Dose...

Rifampin (RIF), the cornerstone of TB treatment, has very problematic drug-drug interactions with PIs. The use of relatively...

Read More